Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

British Journal of Cancer (2)
Communications Medicine (1)
BJC Reports (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (4)

Subject Check one or more subjects to show results from those subjects only.

Cancer
Diseases
Drug discovery
Health care
Medical research
Oncology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–4 of 4 results

Advanced filters: Author: Amita Patnaik Clear advanced filters

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours

J. Randolph Hecht
Jean-Marie Michot
Susanna Ulahannan
ResearchOpen Access27 Feb 2025
BJC Reports

Volume: 3, P: 1-11
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors

Mahalingam et al. report findings from a first-in-human dose escalation study of the tumor microenvironment modulator VT1021 in patients with advanced solid tumors. VT1021 is found to be safe and well tolerated and the recommended phase II dose is established based on pharmacokinetic/dynamic properties and preliminary clinical activities.

Devalingam Mahalingam
Wael Harb
Jing Watnick
ResearchOpen Access13 Jan 2024
Communications Medicine

Volume: 4, P: 1-12
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

A Patnaik
G J Weiss
R K Ramanathan
ResearchOpen Access05 Jun 2014
British Journal of Cancer

Volume: 111, P: 272-280
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Johanna C Bendell
Milind Javle
Amita Patnaik
ResearchOpen Access02 Feb 2017
British Journal of Cancer

Volume: 116, P: 575-583

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

© 2026 Springer Nature Limited